Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes
Guanyue Su, Silin Li, Donghua Zhang, Yongjian Zhou, Ling Wang, Yiqiang Yuan, Guowu Qian, Guotao Li, Na Han, Ming Cheng, Guangming Li, Shixi Zhang, Hong Luo, Mengzhao Yang, Yanyang Zhang, Zhan Song, Jiyuan Xing, Zujiang Yu, Zhigang Ren
iScience, doi:10.1016/j.isci.2025.111907
Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir
AUTHOR CONTRIBUTIONS Conceptualization: Z.R. and Z.Y.; resources: Z.R., Z.Y., J.X, Y.Y., H.L., S.Z., G.L., D.Z., and G.L.; data curation: G.S., M.Y., Y.Z., M.C., L.W., N.H., Z.S., G.Q., and Y.Z.; formal analysis: M.Y.; supervision: Z.R. and Z.Y.; funding acquisition: G.S., Z.R., and Z.Y.; writing-original draft: G.S., S.L., and D.Z.; writing-review and editing: G.S., S.L., and D.Z.
DECLARATION OF INTERESTS The authors declare no competing interests.
STAR+METHODS Detailed methods are provided in the online version of this paper and include the following:
STAR+METHODS KEY RESOURCES TABLE EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS
Ethics approval and consent to participate This study was reviewed and approved by the Institutional Review Board from The First Affiliated Hospital of Zhengzhou University (2023-KY-0865-001). The retrospective cohort study employing anonymized data did not require individual informed consent.
Study design and participants This is a multi-center, retrospective cohort study comparing the effectiveness and safety of azvudine with nirmatrelvir-ritonavir in hospitalized patients with COVID-19 with pre-existing diabetes. We retrieved all hospitalized patients with COVID-19 from nine hospitals in Henan Province (e.g., the First Affiliated Hospital of Zhengzhou University, Henan Provincial Chest Hospital, Henan Infectious Disease Hospital, Luoyang Central Hospital, Nanyang Central Hospital, the Fifth People's Hospital of Anyang, Shangqiu..
References
Aggarwal, Molina, Beaty, Bennett, Carlson et al., Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study, Lancet Infect. Dis,
doi:10.1016/S1473-3099(23)00011-7Arbel, Wolff Sagy, Hoshen, Battat, Lavie et al., Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge, N. Engl. J. Med,
doi:10.1056/NEJMoa2204919Dalva-Aydemir, Bajpai, Martinez, Adekola, Kandela et al., Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin, Clin. Cancer Res,
doi:10.1158/1078-0432.CCR-14-1088De Souza, Cabral, Da Silva, Arruda, Cabral et al., Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients, Front. Med,
doi:10.3389/fmed.2023.1215916Deng, Li, Sun, Jin, Zhou et al., Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study, J. Med. Virol,
doi:10.1002/jmv.28756Dian, Meng, Sun, Deng, Zeng, Azvudine versus Nirmatrelvir-ritonavir for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities, J. Infect,
doi:10.1016/j.jinf.2023.05.012Docherty, Harrison, Green, Hardwick, Pius et al., Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ,
doi:10.1136/bmj.m1985Gao, Luo, Ren, Duan, Han et al., Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19, J. Infect,
doi:10.1016/j.jinf.2023.03.023Hammond, Leister-Tebbe, Gardner, Abreu, Bao et al., Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2118542Kumar, Arora, Sharma, Anikhindi, Bansal et al., Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis, Diabetes Metab. Syndr,
doi:10.1016/j.dsx.2020.04.044Li, Gao, You, Zhang, Pan et al., Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19), Clin. Infect. Dis,
doi:10.1093/cid/ciac600Lui, Chung, Lau, Lau, Au et al., Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong, JAMA Netw. Open,
doi:10.1001/jamanetworkopen.2023.14393Owen, Allerton, Anderson, Aschenbrenner, Avery et al., An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the iScience 28, 111907, Science,
doi:10.1126/science.abl4784Ren, Luo, Yu, Song, Liang et al., A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study, Adv. Sci,
doi:10.1002/advs.202001435Saha, Al-Rifai, Saha, Diabetes prevalence and mortality in COVID-19 patients: a systematic review, meta-analysis, and metaregression, J. Diabetes Metab. Disord,
doi:10.1007/s40200-021-00779-2Su, Yang, Wang, Azvudine versus nirmatrelvir-ritonavir for oral treatment of COVID-19 in Chinese patients, BMC Infect. Dis,
doi:10.1186/s12879-023-08828-2Sun, Jin, Dian, Shen, Zeng et al., Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study, eClinicalMedicine,
doi:10.1016/j.eclinm.2023.101981Wei, Zeng, Wang, Gui, Zhang et al., Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching, Front. Pharmacol,
doi:10.3389/fphar.2023.1274294Wiersinga, Rhodes, Cheng, Peacock, Prescott et al., Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review, JAMA,
doi:10.1001/jama.2020.12839Zhang, Li, Wang, Liu, Lu et al., Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients, Signal Transduct. Target. Ther,
doi:10.1038/s41392-021-00835-6DOI record:
{
"DOI": "10.1016/j.isci.2025.111907",
"ISSN": [
"2589-0042"
],
"URL": "http://dx.doi.org/10.1016/j.isci.2025.111907",
"alternative-id": [
"S2589004225001671"
],
"article-number": "111907",
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "iScience"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/j.isci.2025.111907"
},
{
"label": "Content Type",
"name": "content_type",
"value": "article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2025 The Author(s). Published by Elsevier Inc."
}
],
"author": [
{
"affiliation": [],
"family": "Su",
"given": "Guanyue",
"sequence": "first"
},
{
"affiliation": [],
"family": "Li",
"given": "Silin",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhang",
"given": "Donghua",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhou",
"given": "Yongjian",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wang",
"given": "Ling",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Yuan",
"given": "Yiqiang",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Qian",
"given": "Guowu",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Li",
"given": "Guotao",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Han",
"given": "Na",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Cheng",
"given": "Ming",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Li",
"given": "Guangming",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhang",
"given": "Shixi",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Luo",
"given": "Hong",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Yang",
"given": "Mengzhao",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhang",
"given": "Yanyang",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Song",
"given": "Zhan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Xing",
"given": "Jiyuan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Yu",
"given": "Zujiang",
"sequence": "additional"
},
{
"ORCID": "https://orcid.org/0000-0003-0798-3444",
"affiliation": [],
"authenticated-orcid": false,
"family": "Ren",
"given": "Zhigang",
"sequence": "additional"
}
],
"container-title": "iScience",
"container-title-short": "iScience",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"cell.com",
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2025,
1,
28
]
],
"date-time": "2025-01-28T00:10:20Z",
"timestamp": 1738023020000
},
"deposited": {
"date-parts": [
[
2025,
2,
22
]
],
"date-time": "2025-02-22T00:40:29Z",
"timestamp": 1740184829000
},
"indexed": {
"date-parts": [
[
2025,
2,
22
]
],
"date-time": "2025-02-22T01:10:18Z",
"timestamp": 1740186618813,
"version": "3.37.3"
},
"is-referenced-by-count": 0,
"issue": "2",
"issued": {
"date-parts": [
[
2025,
2
]
]
},
"journal-issue": {
"issue": "2",
"published-print": {
"date-parts": [
[
2025,
2
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2025,
2,
1
]
],
"date-time": "2025-02-01T00:00:00Z",
"timestamp": 1738368000000
}
},
{
"URL": "https://www.elsevier.com/legal/tdmrep-license",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2025,
2,
1
]
],
"date-time": "2025-02-01T00:00:00Z",
"timestamp": 1738368000000
}
},
{
"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2025,
1,
23
]
],
"date-time": "2025-01-23T00:00:00Z",
"timestamp": 1737590400000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S2589004225001671?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S2589004225001671?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "111907",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2025,
2
]
]
},
"published-print": {
"date-parts": [
[
2025,
2
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"DOI": "10.1001/jama.2020.12839",
"article-title": "Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review",
"author": "Wiersinga",
"doi-asserted-by": "crossref",
"first-page": "782",
"journal-title": "JAMA",
"key": "10.1016/j.isci.2025.111907_bib1",
"volume": "324",
"year": "2020"
},
{
"DOI": "10.1126/science.abm4915",
"article-title": "The changing epidemiology of SARS-CoV-2",
"author": "Koelle",
"doi-asserted-by": "crossref",
"first-page": "1116",
"journal-title": "Science",
"key": "10.1016/j.isci.2025.111907_bib2",
"volume": "375",
"year": "2022"
},
{
"DOI": "10.1186/s12979-020-00192-y",
"article-title": "SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done?",
"author": "Mazucanti",
"doi-asserted-by": "crossref",
"first-page": "21",
"journal-title": "Immun. Ageing",
"key": "10.1016/j.isci.2025.111907_bib3",
"volume": "17",
"year": "2020"
},
{
"DOI": "10.1136/bmj.m1985",
"article-title": "Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study",
"author": "Docherty",
"doi-asserted-by": "crossref",
"first-page": "m1985",
"journal-title": "BMJ",
"key": "10.1016/j.isci.2025.111907_bib4",
"volume": "369",
"year": "2020"
},
{
"DOI": "10.1007/s40200-021-00779-2",
"article-title": "Diabetes prevalence and mortality in COVID-19 patients: a systematic review, meta-analysis, and meta-regression",
"author": "Saha",
"doi-asserted-by": "crossref",
"first-page": "939",
"journal-title": "J. Diabetes Metab. Disord.",
"key": "10.1016/j.isci.2025.111907_bib5",
"volume": "20",
"year": "2021"
},
{
"DOI": "10.1016/j.dsx.2020.04.044",
"article-title": "Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis",
"author": "Kumar",
"doi-asserted-by": "crossref",
"first-page": "535",
"journal-title": "Diabetes Metab. Syndr.",
"key": "10.1016/j.isci.2025.111907_bib6",
"volume": "14",
"year": "2020"
},
{
"DOI": "10.1146/annurev-med-052422-020316",
"article-title": "Treatments for COVID-19",
"author": "Andrews",
"doi-asserted-by": "crossref",
"first-page": "145",
"journal-title": "Annu. Rev. Med.",
"key": "10.1016/j.isci.2025.111907_bib7",
"volume": "75",
"year": "2024"
},
{
"DOI": "10.1126/science.abl4784",
"article-title": "An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19",
"author": "Owen",
"doi-asserted-by": "crossref",
"first-page": "1586",
"journal-title": "Science",
"key": "10.1016/j.isci.2025.111907_bib9",
"volume": "374",
"year": "2021"
},
{
"DOI": "10.1056/NEJMoa2204919",
"article-title": "Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge",
"author": "Arbel",
"doi-asserted-by": "crossref",
"first-page": "790",
"journal-title": "N. Engl. J. Med.",
"key": "10.1016/j.isci.2025.111907_bib10",
"volume": "387",
"year": "2022"
},
{
"DOI": "10.1016/S1473-3099(23)00011-7",
"article-title": "Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study",
"author": "Aggarwal",
"doi-asserted-by": "crossref",
"first-page": "696",
"journal-title": "Lancet Infect. Dis.",
"key": "10.1016/j.isci.2025.111907_bib11",
"volume": "23",
"year": "2023"
},
{
"DOI": "10.1093/cid/ciac600",
"author": "Li",
"doi-asserted-by": "crossref",
"first-page": "e148",
"journal-title": "Clin. Infect. Dis.",
"key": "10.1016/j.isci.2025.111907_bib12",
"volume": "76",
"year": "2023"
},
{
"DOI": "10.1001/jamanetworkopen.2023.14393",
"article-title": "Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong",
"author": "Lui",
"doi-asserted-by": "crossref",
"journal-title": "JAMA Netw. Open",
"key": "10.1016/j.isci.2025.111907_bib13",
"volume": "6",
"year": "2023"
},
{
"article-title": "Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal. Transduct",
"author": "Yu",
"first-page": "236",
"journal-title": "Target Ther",
"key": "10.1016/j.isci.2025.111907_bib14",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.3389/fmed.2023.1215916",
"article-title": "Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients",
"author": "de Souza",
"doi-asserted-by": "crossref",
"journal-title": "Front. Med.",
"key": "10.1016/j.isci.2025.111907_bib15",
"volume": "10",
"year": "2023"
},
{
"DOI": "10.1002/advs.202001435",
"article-title": "A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study",
"author": "Ren",
"doi-asserted-by": "crossref",
"journal-title": "Adv. Sci.",
"key": "10.1016/j.isci.2025.111907_bib16",
"volume": "7",
"year": "2020"
},
{
"DOI": "10.1016/j.eclinm.2023.101981",
"article-title": "Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study",
"author": "Sun",
"doi-asserted-by": "crossref",
"journal-title": "eClinicalMedicine",
"key": "10.1016/j.isci.2025.111907_bib17",
"volume": "59",
"year": "2023"
},
{
"DOI": "10.1056/NEJMoa2118542",
"article-title": "Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19",
"author": "Hammond",
"doi-asserted-by": "crossref",
"first-page": "1397",
"journal-title": "N. Engl. J. Med.",
"key": "10.1016/j.isci.2025.111907_bib18",
"volume": "386",
"year": "2022"
},
{
"DOI": "10.1186/s12879-023-08828-2",
"article-title": "Azvudine versus nirmatrelvir-ritonavir for oral treatment of COVID-19 in Chinese patients",
"author": "Su",
"doi-asserted-by": "crossref",
"first-page": "44",
"journal-title": "BMC Infect. Dis.",
"key": "10.1016/j.isci.2025.111907_bib19",
"volume": "24",
"year": "2024"
},
{
"DOI": "10.1016/j.jinf.2023.05.012",
"article-title": "Azvudine versus Nirmatrelvir-ritonavir for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities",
"author": "Dian",
"doi-asserted-by": "crossref",
"first-page": "e24",
"journal-title": "J. Infect.",
"key": "10.1016/j.isci.2025.111907_bib20",
"volume": "87",
"year": "2023"
},
{
"DOI": "10.1002/jmv.28756",
"article-title": "Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study",
"author": "Deng",
"doi-asserted-by": "crossref",
"journal-title": "J. Med. Virol.",
"key": "10.1016/j.isci.2025.111907_bib21",
"volume": "95",
"year": "2023"
},
{
"DOI": "10.1038/s41392-021-00835-6",
"article-title": "Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients",
"author": "Zhang",
"doi-asserted-by": "crossref",
"first-page": "414",
"journal-title": "Signal Transduct. Target. Ther.",
"key": "10.1016/j.isci.2025.111907_bib22",
"volume": "6",
"year": "2021"
},
{
"DOI": "10.3389/fphar.2023.1274294",
"article-title": "Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching",
"author": "Wei",
"doi-asserted-by": "crossref",
"journal-title": "Front. Pharmacol.",
"key": "10.1016/j.isci.2025.111907_bib23",
"volume": "14",
"year": "2023"
},
{
"DOI": "10.1016/j.jinf.2023.03.023",
"article-title": "Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19",
"author": "Gao",
"doi-asserted-by": "crossref",
"first-page": "e158",
"journal-title": "J. Infect.",
"key": "10.1016/j.isci.2025.111907_bib24",
"volume": "86",
"year": "2023"
},
{
"DOI": "10.1158/1078-0432.CCR-14-1088",
"article-title": "Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin",
"author": "Dalva-Aydemir",
"doi-asserted-by": "crossref",
"first-page": "1161",
"journal-title": "Clin. Cancer Res.",
"key": "10.1016/j.isci.2025.111907_bib25",
"volume": "21",
"year": "2015"
}
],
"reference-count": 24,
"references-count": 24,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S2589004225001671"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes",
"type": "journal-article",
"update-policy": "https://doi.org/10.1016/elsevier_cm_policy",
"volume": "28"
}
